Abstract
Since its discovery as the first human oncogene in 1983, the small GTPase KRAS has been a major target of cancer drug discovery. The paper reported in this issue describes a long-awaited small molecule drug candidate of the oncogenic KRAS (G12D) mutant for the treatment of currently incurable pancreatic cancer.
MeSH terms
-
Alleles
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Drug Discovery
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Mutation
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / genetics*
-
Proto-Oncogene Proteins p21(ras) / drug effects*
-
Proto-Oncogene Proteins p21(ras) / genetics*
Substances
-
Antineoplastic Agents
-
KRAS protein, human
-
Proto-Oncogene Proteins p21(ras)